Market capitalization | $949.38m |
Enterprise Value | $948.46m |
P/E (TTM) P/E ratio | 383.97 |
EV/FCF (TTM) EV/FCF | 47.61 |
EV/Sales (TTM) EV/Sales | 4.86 |
P/S ratio (TTM) P/S ratio | 4.86 |
P/B ratio (TTM) P/B ratio | 13.42 |
Revenue growth (TTM) Revenue growth | 15.78% |
Revenue (TTM) Revenue | $195.16m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Enfusion forecast:
10 Analysts have issued a Enfusion forecast:
Sep '24 |
+/-
%
|
||
Revenue | 195 195 |
16%
16%
|
|
Gross Profit | 131 131 |
16%
16%
|
|
EBITDA | 17 17 |
30%
30%
|
EBIT (Operating Income) EBIT | 6.71 6.71 |
40%
40%
|
Net Profit | 3.34 3.34 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded in 2006 and is headquartered in Chicago, IL.
Head office | United States |
CEO | Oleg Movchan |
Employees | 1,102 |
Founded | 2006 |
Website | enfusion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.